Every Form 4 that Relmada Therapeutics, Inc. (RLMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RLMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLMD filings page.
RELMADA THERAPEUTICS, INC. (RLMD) reported that its Chief Financial Officer, Maged Shenouda, purchased a total of 200,000 shares of common stock in open market transactions on September 9 and 10, 2026. Purchases were made around $4.20–$4.25 per share, and no Rule 10b5-1 trading plan is reported.
RELMADA THERAPEUTICS, INC. (RLMD) director and Chief Executive Officer Sergio Traversa reported open-market purchases of the company’s common stock on two consecutive days. On September 9, 2026, he purchased 100,000 shares at a weighted average price of $4.18 per share, with individual trade prices ranging from $4.15 to $4.22. On September 10, 2026, he purchased an additional 100,000 shares at a weighted average price of $4.10 per share, with trade prices ranging from $4.03 to $4.11. No Rule 10b5-1 trading plan is reported for these transactions.
Relmada Therapeutics CEO and director Sergio Traversa reported buying 27,500 shares of the company’s common stock in multiple open market transactions at a weighted average price of $4.12 per share, with individual purchase prices ranging from $4.10 to $4.12.
Following these purchases, he beneficially owns 1,300,000 common shares directly. Traversa was also granted 1,198,000 stock appreciation rights with a conversion price of $4.06, each linked to one share of common stock. These rights vest in 16 equal quarterly installments beginning on March 12, 2026 and expire on December 12, 2035, with 1,198,000 derivative securities shown as beneficially owned after the transaction.
Relmada Therapeutics, Inc.'s chief financial officer reported buying 11,665 shares of common stock on December 15, 2025 at $4.12 per share, bringing his directly held stake to 800,000 shares. In a separate transaction on December 12, 2025, he was granted 828,000 stock appreciation rights with a $4.06 exercise price, each linked to one share of common stock and expiring on December 12, 2035. These rights begin vesting on March 12, 2026 in 16 equal quarterly installments, providing additional long-term equity-based compensation tied to the company’s stock.
Relmada Therapeutics, Inc. reported that one of its officers with the title "CA and CO" received 828,000 stock appreciation rights12/12/2025$4.0603/12/202612/12/203516 equal quarterly installments828,000 derivative securities
Relmada Therapeutics director Fabiana Fedeli reported receiving a grant of 164,000 stock appreciation rights on December 12, 2025. These derivative securities relate to Relmada Therapeutics common stock and carry an exercise price of $4.06 per right. The award was reported as an acquisition transaction and is held with direct ownership.
The stock appreciation rights are scheduled to vest in 16 equal quarterly installments, commencing on March 12, 2026, providing a staged vesting profile over time. The instruments become exercisable starting March 12, 2026 and have an expiration date of December 12, 2035, giving a long-dated window in which they may be exercised.
Relmada Therapeutics director John Glasspool reported a new equity award in the form of stock appreciation rights. On 12/12/2025, he was granted 164,000 stock appreciation rights with a conversion or exercise price of $4.06, each tied to one share of Relmada common stock.
The award is structured as a long-term incentive. It begins vesting on March 12, 2026, in 16 equal quarterly installments and expires on 12/12/2035. Following this grant, Glasspool beneficially owns 164,000 derivative securities directly, all linked to Relmada’s common stock.
Relmada Therapeutics director and COO Paul Kelly reported receiving 828,000 stock appreciation rights tied to the company’s common stock. These rights were granted on December 12, 2025 with an exercise price of $4.06 and expire on December 12, 2035.
The stock appreciation rights vest in 16 equal quarterly installments starting March 12, 2026, so portions of the award become exercisable over time. After this grant, Kelly beneficially owns 828,000 derivative securities directly, linking part of his compensation to Relmada’s future share performance.
Relmada Therapeutics, Inc. reported an insider equity award to one of its directors. On 12/12/2025, the director received stock appreciation rights tied to 164,000 shares of common stock with a base price of $4.06 per share.
These stock appreciation rights begin vesting in 16 equal quarterly installments starting on March 12, 2026, and are scheduled to expire on December 12, 2035. The award was reported as directly owned by the director.
Relmada Therapeutics (RLMD) filed a Form 4 showing an insider purchase. The company’s Chief Financial Officer, Maged Shenouda, purchased 500,000 shares of common stock on 11/05/2025 at a price of $2.2 per share, coded “P” for purchase.
Following the transaction, beneficial ownership stood at 788,335 shares, reported as direct ownership. The filing reflects a personal share acquisition by a senior officer and updates the executive’s current holdings.
Relmada Therapeutics (RLMD) Form 4: An officer serving as CAO and COO reported an open-market purchase (transaction code P) of 136,000 shares of common stock on 11/05/2025 at $2.2 per share. Following the transaction, the reporting person beneficially owns 403,931 shares, held directly. The filing indicates a single reporting person and relates to Relmada Therapeutics, Inc.
Relmada Therapeutics (RLMD) insider activity: Chief Executive Officer and Director Sergio Traversa reported a purchase of 272,500 shares of Common Stock on 11/05/2025 at $2.2 per share (transaction code P).
Following the trade, he beneficially owns 1,272,500 shares, held directly. This Form 4 reflects an open-market or private purchase and updates his direct ownership position.
Relmada Therapeutics (RLMD) insider activity: Chief Operating Officer and Director Paul Kelly purchased 90,000 shares of common stock at $2.2 on 11/05/2025. Following the transaction, he directly beneficially owns 502,295 shares.